Overview
A U.S. judge on Tuesday determined that Novo Nordisk A/S must face parts of a securities fraud class action that alleges the company misled shareholders about the clinical development of CagriSema, its treatment for weight loss and diabetes.
Allegations and scope
The complaint focuses on statements and conduct connected to the Phase 3 clinical study called REDEFINE-1. The case covers a class period running from November 2, 2022, through December 19, 2024. Plaintiffs assert that, during that timeframe, company executives publicly conveyed a high degree of confidence that CagriSema would achieve a minimum average weight loss of 25 percent.
Plaintiffs further contend that Novo Nordisk did not disclose an element of the REDEFINE-1 protocol that allowed patients to change their own dosages in response to tolerability issues. That omission is central to the portions of the fraud claims the judge allowed to proceed.
What the ruling means
The court's decision clears the way for parts of the securities fraud allegations tied to the REDEFINE-1 trial and the specific disclosure claims to move forward in the litigation. The ruling does not resolve the merits of the underlying accusations but permits further legal proceedings on the permitted claims.
Context preserved by the complaint
The complaint frames the dispute around investor communications and the content of the REDEFINE-1 trial protocol. It identifies a precise class period and specifies the contested public statements about expected weight-loss outcomes, as well as the alleged nondisclosure regarding patient-managed dosage adjustments for tolerability.
Next steps
With this ruling, the permitted aspects of the class action can proceed through the court system. The decision does not itself determine liability or damages; it allows plaintiffs to pursue discovery and subsequent phases of the lawsuit on the issues the judge deemed appropriately pleaded.
Note: The article reports on the court ruling and the allegations as described in the complaint. It does not address or decide the truth of the claims.